Home > Publications database > Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative. > print

001     125509
005     20240228143312.0
024 7 _ |a 10.1159/000449412
|2 doi
024 7 _ |a pmid:27756074
|2 pmid
024 7 _ |a 0012-2823
|2 ISSN
024 7 _ |a 0301-164X
|2 ISSN
024 7 _ |a 0365-8228
|2 ISSN
024 7 _ |a 0365-8325
|2 ISSN
024 7 _ |a 1421-9867
|2 ISSN
037 _ _ |a DKFZ-2017-01635
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Betge, Johannes
|0 P:(DE-He78)68cbca3e3973d332ccc4c6e31a76b10c
|b 0
|e First author
|u dkfz
245 _ _ |a Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.
260 _ _ |a Basel
|c 2016
|b Karger
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1521807297_19902
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a This study is aimed at analyzing the survival rates and prognostic factors of stage IV colorectal cancer patients from 3 European cohorts undergoing combination chemotherapy with bevacizumab.Progression free-survival (PFS) and overall survival (OS) were analyzed in 172 patients using the Kaplan-Meier method and uni- and multivariable Cox proportional hazards regression models.The median PFS was 9.7 and the median OS 27.4 months. Patients treated at centers in Germany (n = 97), Ireland (n = 32), and The Netherlands (n = 43) showed a median PFS of 9.9, 9.2, and 9.7 months, OS of 34.0, 20.5, and 25.1 months, respectively. Patients >65 years had a significantly shorter PFS (9.5 vs. 9.8 months) but not OS (27.4 vs. 27.5 months) than younger patients. High tumor grade (G3/4) was associated with a shorter PFS, T4 classification with both shorter PFS and OS. Fluoropyrimidine (FP) chemotherapy backbones (doublets and single) had comparable outcomes, while patients not receiving FP backbones had a shorter PFS. In multivariable analysis, age and non-FP backbone were associated with inferior PFS, T4 classification and therapy line >2nd were significantly associated with poor PFS and OS.The observed survival rates confirm previous studies and demonstrate reproducible benefits of combination bevacizumab regimens. Classification T4, non-FP chemotherapy backbone, and age >65 were associated with inferior outcome.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Angiogenesis Inhibitors
|2 NLM Chemicals
650 _ 7 |a Pyrimidines
|2 NLM Chemicals
650 _ 7 |a Bevacizumab
|0 2S9ZZM9Q9V
|2 NLM Chemicals
650 _ 7 |a 5-fluoropyrimidine
|0 675-21-8
|2 NLM Chemicals
700 1 _ |a Barat, Ana
|b 1
700 1 _ |a Murphy, Verena
|b 2
700 1 _ |a Hielscher, Thomas
|0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
|b 3
|u dkfz
700 1 _ |a Van Grieken, Nicole C
|b 4
700 1 _ |a Belle, Sebastian
|b 5
700 1 _ |a Zhan, Tianzuo
|0 P:(DE-He78)4730a4e3dbc9057824efb4d2be729786
|b 6
|u dkfz
700 1 _ |a Härtel, Nicolai
|b 7
700 1 _ |a Kripp, Melanie
|b 8
700 1 _ |a Bacon, Orna
|b 9
700 1 _ |a Cordes, Martijn
|b 10
700 1 _ |a Kay, Elaine W
|b 11
700 1 _ |a Verheul, Henk M W
|b 12
700 1 _ |a Neerincx, Maarten
|b 13
700 1 _ |a Hennessy, Bryan
|b 14
700 1 _ |a Hofheinz, Ralf D
|b 15
700 1 _ |a Gaiser, Timo
|b 16
700 1 _ |a Ylstra, Bauke
|b 17
700 1 _ |a Prehn, Jochen H M
|b 18
700 1 _ |a Lambrechts, Diether
|b 19
700 1 _ |a Byrne, Annette T
|b 20
700 1 _ |a Ebert, Matthias P
|b 21
700 1 _ |a Schulte, Nadine
|b 22
773 _ _ |a 10.1159/000449412
|g Vol. 94, no. 3, p. 129 - 137
|0 PERI:(DE-600)1482218-0
|n 3
|p 129 - 137
|t Digestion
|v 94
|y 2016
|x 1421-9867
909 C O |o oai:inrepo02.dkfz.de:125509
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)68cbca3e3973d332ccc4c6e31a76b10c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)4730a4e3dbc9057824efb4d2be729786
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2016
915 _ _ |a Allianz-Lizenz / DFG
|0 StatID:(DE-HGF)0400
|2 StatID
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b DIGESTION : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 0
920 1 _ |0 I:(DE-He78)B110-20160331
|k B110
|l Signalwege und Funktionelle Genomik
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)B110-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21